α-Gal Epitope (Galα1-3Galβ1-4GlcNAc-R), mAb (M86)



ALX-801-090-1	1 Vial	330.00 USD

Widely described antibody against α-galactose residues with broad cross-reactivity among different species. Useful for measuring the α-Gal epitope expression on cells, glycolipids and glycoproteins, characterization of hyperacute rejection (HAR) in organ and tissue transplantations and monitoring xenotransplantation experiments. The IgM isotype mimicks in vivo reactions and can be used for cytotoxicity assays for α-Gal specific pathways (addition or presence of complement necessary).

Alternative Name:	α-Galactose 1,3

Formulation:	Liquid. Tissue culture supernatant.

Clone:	M86

Isotype:	Mouse IgM

Immunogen:	Rabbit red blood cell membrane.

Source/Host:	Hybridoma tissue culture.

Specificity:	Recognizes synthetic and naturally produced mouse, rat and pig Galα1-3Gal epitopes on glycoproteins and glycolipids. Does not cross-react with β-Gal glycoproteins or BSA.

Application:	ELISA Flow Cytometry Immunohistochemistry (paraffin sections) Western Blot Functional Application (can be used for cytotoxicity assays for α-Gal specific pathways) Note: Do not use non-fat milk for blocking! Many blocking agents from non-human mammal sources will cross-react with the antibody. Appropriate antibody dilution may vary from lot to lot. An initial dilution of 1:5 is recommended. Optimal conditions must be determined individually for each application.

Long Term Storage:	-20°C

Use/Stability:	Stable for at least 3 years when stored at -20°C.

Handling:	After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.

Product Literature References

Generation of bioengineered corneas with decellularized xenografts and human keratocytes: M. Gonzalez-Andrades, et al.; Invest. Ophthalmol. Vis. Sci. 52, 215 (2011), Abstract; Full Text

Brief report: a new profile of terminal N-acetyllactosamines glycans on pig red blood cells and different expression of alpha-galactose on Sika deer red blood cells and nucleated cells: Y. Tan, et al.; Glycoconj. J. 27, 427 (2010), Abstract;

First quantitative assay of alpha-Gal in soft tissues: presence and distribution of the epitope before and after cell removal from xenogeneic heart valves: F. Naso, et al.; Acta Biomater. 7, 1728 (2010), Abstract;

The retention of extracellular matrix proteins and angiogenic and mitogenic cytokines in a decellularized porcine dermis: D.M. Hoganson, et al.; Biomaterials 31, 6730 (2010), Abstract;

A novel method to display [gal alpha1, 3 gal] antigens on human leukemic cells for preparation of anti-leukemia vaccines: K.J. Posekany, et al.; Anticancer Res. 29, 2387 (2009), Abstract;

Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes: U. Abdel-Motal, et al.; J. Virol. 80, 6943 (2006), Abstract; Full Text

Lack of Galactose-alpha-1,3-Galactose Expression on Porcine Endothelial Cells Prevents Complement-Induced Lysis but Not Direct Xenogeneic NK Cytotoxicity: B.C. Baumann, et al.; J. Immunol. 172, 6460 (2004), Abstract;

Differential expression of Galalpha1,3Gal epitopes on fetal and adult porcine hematopoietic cells: S. Gojo, et al.; Xenotransplantation 9, 297 (2002), Abstract; Full Text

Expression of alpha-gal epitopes on HeLa cells transduced wtih adenovirus containing alpha-1,3galactosyltransferase cDNA: L. Deriy, et al.; Glycobiology 12, 135 (2002), Abstract;

Remodeling of the Major Pig Xenoantigen by N-Actetylglucosaminyltransferase III in Transgenic Pig: S. Miyagawa, et al.; J. Biol. Chem. 276, 39310 (2001), Abstract; Full Text

Synthesis of α-gal epitopes (Galα1-3Galβ1-4GlcNAc-R) on human tumor cells by recombinant α1,3galactosyltransferase produced in Pichia pastoris: Z.C. Chen, et al.; Glycobiology 11, 577 (2001), Abstract; Full Text

The alpha-gal epitope (Gal alpha 1-3Gal beta 1-4GlcNAc-R) in xenotransplantation: U. Galili; Biochemie 83, 557 (2001), Abstract;

Differential expression of alpha-Gal epitopes on pig and mouse organs: M. Tanemura & U. Galili; Transplant. Proc. 32, 843 (2000), Abstract;

Differential immune responses to alpha-gal epitopes on xenografts and allografts: implications for accommodation in xenotransplantation: M. Tanemura, et al.; J. Clin. Invest. 105, 301 (2000), Abstract;

Mechanism of delayed rejection in transgenic pig-to-primate cardiac xenotransplantation: R.H. Chen, et al.; J. Surg. Res. 90, 119 (2000), Abstract;

Xenotransplantation: in vitro analysis of synthetic alpha-galactosyl inhibitors of human anti-Galalpha1-->3Gal IgM and IgG antibodies: R. Rieben, et al.; Glycobiology 10, 141 (2000), Abstract;

alpha-Gal Oligosaccharides: Chemistry and Potential Biomedical Application: A. Janczuk, et al.; Current Med. Chem. 6, 155 (1999), Abstract;

Regulation of natural killer cell-mediated swine endothelial cell lysis through genetic remodeling of a glycoantigen: S. Miyagawa, et al.; J. Biochem. 126, 1067 (1999), Abstract;

A sensitive assay for measuring alpha-Gal epitope expression on cells by a monoclonal anti-Gal antibody: U. Galili, et al.; Transplantation 65, 1129 (1998), Abstract;